2014 AACR Special Conference on Pancreatic Cancer

Pancreatic Cancer

Early Study Finds BRCA-Mutated Pancreatic Cancer Responds to PARP Inhibition Trio

Two-thirds of patients with advanced pancreatic adenocarcinoma who harbored BRCA mutations responded to the combination of veliparib, cisplatin, and gemcitabine in a phase IB trial that is paving the ...

Advertisement

Advertisement



Advertisement